Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Feb 1;97(2):E40-E44.
doi: 10.1002/ajh.26404. Epub 2021 Dec 6.

Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study

Guillaume Moulis  1   2 , Johanne Germain  2 , Manuela Rueter  2 , Margaux Lafaurie  2   3 , Myriam Aroichane  4 , Thibault Comont  5 , Matthieu Mahévas  6 , Jean-François Viallard  7 , Stéphane Chèze  8 , Mikaël Ebbo  9 , Sylvain Audia  10 , Soraya Leclerc-Teffahi  4 , Agnès Sommet  2   3 , Odile Beyne-Rauzy  4 , Marc Michel  5 , Bertrand Godeau  5 , Maryse Lapeyre-Mestre  2   3 ; CARMEN investigators group
Collaborators, Affiliations
Multicenter Study

Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study

Guillaume Moulis et al. Am J Hematol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

This study was granted by Novartis SAS. The design of the ELEXTRA study, protocol, and statistical analyses plan were made by GM, MA, and SLT. Novartis SAS had no access to data and no role in analysis, interpretation of results and manuscript writing. The present manuscript has been sent to Novartis SAS representatives before submission, with no substantial modification requested from the authors. GM received meeting attendance grants from Amgen and Novartis, is coordinator of research studies granted by Amgen, CSL Behring, Novartis and Grifols. He participated in educational sessions funded by Amgen and Novartis, and to boards for Amgen, Novartis and Sobi. TC received honoraria and/or research or educational support from AbbVie, AstraZeneca, Bristol Myers Squibb (Celgene), Novartis and Takeda. SC is investigator of research studies granted by Bioverativ, Novartis, Protalex, Rigel and participated to boards for Novartis and Sobi. ME received meeting attendance grants from Novartis, Octapharma and Sobi, and participated to educational sessions for Amgen, Grifols, Novartis and to boards for Grifols and Novartis. MMi participated to educational sessions and boards for Amgen, Argenx, Novartis, Sobi, and UCB. BG participated to educational sessions and boards Amgen, Grifols, Novartis, Roche and Sobi. All other authors declare having no conflict of interest.

References

    1. Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381:945‐955. - PubMed
    1. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780‐3817. - PMC - PubMed
    1. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829‐3866. - PMC - PubMed
    1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386‐2393. - PubMed
    1. Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104:1112‐1123. - PMC - PubMed